25.11.2024 16:16:35
|
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.
Under the programme initiated 11 November 2024, Novo Nordisk will repurchase B shares for an amount up to DKK 3,136,206,122.30 in the period from 11 November 2024 to 3 February 2025.
Since the announcement 18 November 2024, the following transactions have been made:
Number of B shares | Average purchase price | Transaction value, DKK | |
Accumulated, last announcement | 431,987 | 322,447,007 | |
18 November 2024 | 80,000 | 707.75 | 56,619,914 |
19 November 2024 | 80,000 | 708.89 | 56,711,046 |
20 November 2024 | 80,000 | 732.74 | 58,619,356 |
21 November 2024 | 80,000 | 727.27 | 58,181,804 |
22 November 2024 | 80,000 | 738.07 | 59,045,300 |
Accumulated under the programme | 831,987 | 611,624,426 |
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
With the transactions stated above, Novo Nordisk owns a total of 22,179,644 B shares of DKK 0.10 as treasury shares, corresponding to 0.5% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February 2024. As of 22 November 2024, Novo Nordisk has since 6 February 2024 repurchased a total 21,035,086 B shares at an average share price of DKK 830.77 per B share equal to a transaction value of DKK 17,475,418,304.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com,
Facebook, Instagram, X, LinkedIn and
YouTube.
Contacts for further information
Media: | |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com |
Investors: | |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | David Heiberg Landsted
+45 3077 6915 dhel@novonordisk.com |
Sina Meyer +45 3079 6656 azey@novonordisk.com | Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com |
Frederik Taylor Pitter +1 609 613 0568 fptr@novonordisk.com |
Company announcement No 91/2024
Attachments
Nachrichten zu Novo Nordisk
13.01.25 |
Minuszeichen in Europa: So entwickelt sich der STOXX 50 nachmittags (finanzen.ch) | |
13.01.25 |
Börse Europa in Rot: STOXX 50 legt am Montagmittag den Rückwärtsgang ein (finanzen.ch) | |
13.01.25 |
Minuszeichen in Europa: STOXX 50 zeigt sich zum Start des Montagshandels schwächer (finanzen.ch) | |
10.01.25 |
Börse Europa in Rot: STOXX 50 sackt schlussendlich ab (finanzen.ch) | |
10.01.25 |
STOXX 50 aktuell: STOXX 50 gibt am Nachmittag nach (finanzen.ch) | |
10.01.25 |
Anleger in Europa halten sich zurück: STOXX 50 zeigt sich schwächer (finanzen.ch) | |
10.01.25 |
Börse Europa in Rot: STOXX 50 zum Handelsstart in Rot (finanzen.ch) | |
09.01.25 |
STOXX 50-Handel aktuell: Zum Ende des Donnerstagshandels Gewinne im STOXX 50 (finanzen.ch) |
Analysen zu Novo Nordisk
13.01.25 | Novo Nordisk Buy | UBS AG | |
10.01.25 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
10.01.25 | Novo Nordisk Buy | Deutsche Bank AG | |
08.01.25 | Novo Nordisk Buy | UBS AG | |
07.01.25 | Novo Nordisk Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) |
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
NEU✅ Wolters Kluwer
NEU✅ American Express
NEU✅ Deckers Outdoor
inklusive Rebalancing:
❌ Synopsys
❌ Vertex Pharmaceuticals Inc
❌ Targa Resources
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
US-Handel endet mit unterschiedlichen Vorzeichen -- SMI beendet Handel im Minus -- DAX schliesst tiefer -- Asiens Börsen letztlich in RotDer heimische Aktienmarkt zeigte sich zum Wochenstart schwächer. Der deutsche Leitindex gab ebenfalls nach. An den US-Märkten ging es am Montag in unterschiedliche Richtungen. In Asien notierten die Börsen am Montag im Minus.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |